Press

Acarix AB recruits Per Persson as Chief Commercial Officer

 

Acarix AB (publ) (“Acarix”), today announced the recruitment of Per Persson as new Chief Commercial Officer.

Acarix AB (publ) (“Acarix”), today announced the recruitment of Per Persson as new Chief Commercial Officer to accelerate the sales execution for the CADScor®System for Coronary Artery Disease (CAD) risk assessment. He has a solid background in sales and marketing of medical technology products in general and in cardiolog

Acarix AB recruits Per Persson as Chief Commercial Officer

 

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix.

For more information, please visit www.acarix.com.